Page 3 - Nasdaq Lumo News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nasdaq lumo. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nasdaq Lumo Today - Breaking & Trending Today

K2 Principal Fund L.P. Sells 40,030 Shares of Lumos Pharma, Inc. (NASDAQ:LUMO)

K2 Principal Fund L.P. reduced its position in Lumos Pharma, Inc. (NASDAQ:LUMO – Get Rating) by 71.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 15,836 shares of the company’s stock after selling 40,030 shares during the quarter. K2 Principal Fund L.P.’s holdings […] ....

Lumos Pharma , Principal Fund , Advisor Group , Exchange Commission , Lumos Pharma Company Profile , Marquette Asset Management , Lumos Pharma Inc , Envestnet Asset Management Inc , Get Rating , Asset Management , Visit Holdingschannel , Lumos Pharma Daily , Nasdaq Lumo , Sec Filings , Hedge Fund Holdings , Institutional Investor Holdings ,

Critical Comparison: IDEAYA Biosciences (NASDAQ:IDYA) versus Lumos Pharma (NASDAQ:LUMO)

Lumos Pharma (NASDAQ:LUMO – Get Rating) and IDEAYA Biosciences (NASDAQ:IDYA – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership. Risk & Volatility Lumos Pharma has a beta of […] ....

Lumos Pharma , Jeffrey Hager , Yujiros Hata , Lumos Pharma Inc , Biosciences Inc , Get Rating , Given Lumos Pharma , South San Francisco , Lumos Pharma Daily , Nasdaq Lumo , Stock Comparison , Stock Analysis ,

Q2 2023 EPS Estimates for Lumos Pharma, Inc. (NASDAQ:LUMO) Raised by Analyst

Lumos Pharma, Inc. (NASDAQ:LUMO – Get Rating) – Equities research analysts at HC Wainwright upped their Q2 2023 EPS estimates for shares of Lumos Pharma in a research report issued on Thursday, May 4th. HC Wainwright analyst E. White now anticipates that the company will post earnings of ($0.99) per share for the quarter, up […] ....

Lumos Pharma , Millennium Management , Greenwich Wealth Management , Lumos Pharma Inc , Lumos Pharma Company Profile , Virtu Financial , Marquette Asset Management , Shay Capital , Get Rating , Pharma Trading Down , Asset Management , Wealth Management , Lumos Pharma Daily , Nasdaq Lumo , Earnings Estimates , Hc Wainwright ,

Lumos Pharma (LUMO) to Release Quarterly Earnings on Wednesday

Lumos Pharma (NASDAQ:LUMO – Get Rating) will be issuing its quarterly earnings data after the market closes on Wednesday, May 3rd. Analysts expect the company to announce earnings of ($1.12) per share for the quarter. Parties that wish to listen to the company’s conference call can do so using this link. Lumos Pharma (NASDAQ:LUMO – […] ....

Lumos Pharma , Advisor Group , Jefferies Financial Group Inc , Lumos Pharma Inc , Virtu Financial , Millennium Management , Shay Capital , Get Rating , Financial Group , Lumos Pharma Daily , Nasdaq Lumo ,

Additional Data on Lumos OraGrowtH Trials Presented

Oral Presentation Highlighting Data on 15 Subjects from OraGrowtH212 Trial Supportive of Conclusions from Interim Data Analysis Baseline Characteristics. ....

Buenos Aires , Distrito Federal , United States , Erick Hawkins , Fernando Cassorla , Lisa Miller , Alison Lunsford , Lumos Pharma , University Of Chile , International Meeting Of Pediatric Endocrinology , Lumos Pharma Inc , Oral Presentation Highlighting Data , Interim Data , Subjects Highlighted , Pediatric Growth Hormone Deficiency , Pediatric Endocrinology , Idiopathic Pediatric , Interim Analysis Data , Idiopathic Pediatric Growth Hormone Deficiency , Assistant Professor , Texas Tech Physicians , Orphan Drug Designation , Private Securities Litigation Reform Act , Annual Report , Quarterly Reports , Media Contact ,